Divi's Laboratories Limited

DIVISLAB

INE361B01024

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 07:43:48 2024-05-10 am EDT			5-day change	1st Jan Change
3,794 ^INR	+0.09%		-3.99%	-2.83%

Apr. 26	Weak March Quarter Earnings Weigh Down Indian Equities on Friday	MT
Apr. 25	Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity	MT

Divi's Laboratories Limited Announces Resignation of Prof. C. Ayyanna as Independent Director

May 20, 2013 at 01:02 pm EDT

Divi's Laboratories Limited announced that Prof. C. Ayyanna, Independent Director of the company has resigned from the Board due to personal reasons and other pre-occupations. The Board has accepted his resignation and appreciated his contribution to the company.

Latest news about Divi's Laboratories Limited

Weak March Quarter Earnings Weigh Down Indian Equities on Friday	Apr. 26	MT
Divi's Laboratories Plans Up To INR7 Billion Investment to Boost Capacity	Apr. 25	MT
Indian Equities Close Higher on Friday, Led by Metal, Banking Stocks	Apr. 19	MT
Indian Equities Close Lower on Friday As Hopes for US Rate Cute in June Fade	Apr. 12	MT
Indian Equities End Higher on Wednesday, Lifted Mainly by Metal Stocks	Apr. 10	MT
Divi's Laboratories Limited Approves Appointment of Dr. S. Devendra Rao as Whole-Time Director (Manufacturing)	Apr. 05	CI
Indian Equities Close with Marginal Loss on Wednesday as Traders Scale Down Hopes on US Rate Cuts	Apr. 03	MT
Indian Equities End Higher on Monday, Led by Gains in Metal, Realty Stocks	Apr. 01	MT
Indian Equities Close Lower on Monday, Draagged by Major Banking, Financial Companies	Feb. 12	MT
INDIA STOCKS-Energy shares drag India's blue-chip stocks; small, mid-caps slide	Feb. 12	RE
Transcript : Divi's Laboratories Limited, Q3 2024 Earnings Call, Feb 10, 2024	Feb. 10
Divi's Laboratories Limited Reports Earnings Results for the Third Quarter and Nine Months Ended December 31, 2023	Feb. 10	CI
Indian Equities Break Five-Day Winning Streak on Tuesday, Dragged by Realty, IT Stocks	Jan. 16	MT
INDIA STOCKS-Indian shares decline amid selling pressure in financials, IT	Jan. 01	RE
Indian Equities End Higher for Third Straight Day on Tuesday, Lifted by US Inflation Drop	Dec. 26	MT
Indian Equities End Higher Midweek, Led by Gains in Bank, Auto and IT Stocks	Nov. 29	MT
Selling in IT Drags Indian Equities to Close Lower on Friday	Nov. 24	MT
INDIA STOCKS-Indian shares lacklustre as IT stocks snap rally	Nov. 23	RE
Profit Booking Amid Weak Global Cues Drags Indian Equities to End Flat on Tuesday	Nov. 07	MT
Jefferies Downgrades Divi’s Laboratories to Hold From Buy, Adjusts Price Target to INR3,510 From INR4,300	Nov. 07	MT
Divi's Laboratories' Consolidated Profit Slides in Fiscal Q2; EPS, Revenue Miss Estimates	Nov. 06	MT
Indian Equities End Higher for Third Time on Monday on Expected Imminent End to Rate Hikes	Nov. 06	MT
Transcript : Divi's Laboratories Limited, Q2 2024 Earnings Call, Nov 06, 2023	Nov. 06
Divi's Laboratories Limited Reports Earnings Results for the Second Quarter and Six Months Ended September 30, 2023	Nov. 06	CI
Potential US Interest Rate Hikes, Israel-Hamas War Drag Indian Equities to End Lower as Week Ends	23-10-20	MT

Chart Divi's Laboratories Limited

Duration

Period

More charts

Company Profile

Divi's Laboratories Limited is specialized in the development and manufacture of active pharmaceutical ingredients, intermediates and nutraceutical ingredients. Net sales by source of revenue break down into product sales (97.9%) and service sales (2.1%). At the end of March 2020, the group has 2 production sites located in India.

Sector

Pharmaceuticals

Calendar

2024-05-26 - Q4 2024 Earnings Release (Projected)

Related indices

NIFTY 50 , NIFTY 100

More about the company

Income Statement Evolution

More financial data

Ratings for Divi's Laboratories Limited

Trading Rating

Investor Rating

ESG Refinitiv

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

HOLD

Number of Analysts

Last Close Price

3,794 INR

Average target price

3,442 INR

Spread / Average Target

-9.26%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
DIVI'S LABORATORIES LIMITED	-2.83%	12.06B
ELI LILLY AND COMPANY	+30.38%	684B
NOVO NORDISK A/S	+26.51%	568B
JOHNSON & JOHNSON	-4.36%	361B
MERCK & CO., INC.	+19.30%	329B
ABBVIE INC.	+3.73%	284B
ASTRAZENECA PLC	+16.70%	240B
NOVARTIS AG	+8.78%	208B
ROCHE HOLDING AG	-7.93%	200B
AMGEN INC.	+7.68%	166B

Other Pharmaceuticals